Papanikolopoulou A, Gargalianos-Kakolyris P, Stoupis A, Moussas N, Pangalis A, Theodoridou K, Chronopoulou G, Pantazis N, Kantzanou M, Maltezou HC, et al. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia, through a Six-Year Infection Control Program in a Hospital. Microorganisms. 2023;11:1315.

Ruiz-Burga E, Tariq S, Touloumi G, Gill J, Nicholls EJ, Sabin C, Mussini C, Meyer L, Anne AV, Carlander C, et al. CASCADE protocol: exploring current viral and host characteristics, measuring clinical and patient-reported outcomes, and understanding the lived experiences and needs of individuals with recently acquired HIV infection through a multicentre mixed-methods. BMJ open. 2023;13:e070837.

Thomadakis C, Yiannoutsos CT, Pantazis N, Diero L, Mwangi A, Musick BS, Wools-Kaloustian K, Touloumi G. The effect of HIV treatment interruption on subsequent immunologic response. American Journal of Epidemiology. 2023:kwad076.

Rizavas IA, Gournellis R, Pantazis N, Chatzinikolaou F, Douzenis P, Efstathiou V, Lagouvardos K, Douzenis A. The impact of meteorological factors on involuntary admission in Attica, Greece. Psychiatriki. 2023.

Thomadakis C, Pantazis N, Touloumi G. Issues with the expected information matrix of linear mixed models provided by popular statistical packages under missingness at random dropout. Statistics in Medicine. 2023.

Pantazis N, Paparizos V, Papastamopoulos V, Metallidis S, Antoniadou A, Adamis G, Psichgiou M, Chini M, Sambatakou H, Chrysos G, et al. Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/μL on ART. PloS one. 2023;18:e0283648.

Venetsanopoulou AI, Kalpourtzi N, Alamanos Y, Gavana M, Vantarakis A, Hadjichristodoulou C, Mouchtouri VA, Chlouverakis G, Trypsianis G, Drosos AA, et al. Prevalence of rheumatoid arthritis in Greece: results from the national health examination survey EMENO. Rheumatology International. 2023:1–7.

Georgakopoulou VE, Pantazis N, Tsiafaki X, Nena E, Amfilochiou A, Steiropoulos P. Validation of NoSAS score for the screening of obstructive sleep apnea. Medicine International. 2023;3:1–10.

Touloumi G, Thomadakis C, Pantazis N, Papastamopoulos V, Paparizos V, Metallidis S, Adamis G, Chini M, Psichogiou M, Chrysos G, et al. HIV continuum of care: bridging cross-sectional and longitudinal analyses. AIDS. 2022;36:583–591.

Diaz FJ, Zhang X, Pantazis N, de Leon J. Measuring Individual Benefits of Medical Treatments Using Longitudinal Hospital Data with Non-Ignorable Missing Responses Caused by Patient Discharge: Application to the Study of Benefits of Pain Management Post Spinal Fusion. Revista Colombiana de Estadistica. 2022;45:275–300.

Giannitsioti E, Salles MJ, Mavrogenis A, Rodriguez-Pardo D, Los-Arcos I, Ribera A, Ariza J, del Toro MD, Nguyen S, Senneville E, et al. Osteosynthesis-associated infection of the lower limbs by multidrug-resistant and extensively drug-resistant Gram-negative bacteria: a multicentre cohort study. Journal of Bone and Joint Infection. 2022;7:279–288.

Parasyris S, Hatzaras I, Ntella V, Sidiropoulos T, Margaris I, Pantazis N, Kokoropoulos P, Vassiliu P, Matsota P, Smyrniotis V, et al. Pancreaticoduodenectomy as a feasible choice for periampullary malignancy in octogenarians. Molecular and Clinical Oncology. 2022;17:1–7.

Christopoulos K, Benetou V, Riza E, Pantazis N. Pet ownership and survival of European older adults. European Journal of Ageing. 2022:1–12.

Papanikolopoulou A, Maltezou HC, Gargalianos-Kakolyris P, Pangalis A, Pantazis N, Pantos C, Tountas Y, Tsakris A, Kantzanou M. Association between consumption of antibiotics, infection control interventions and Clostridioides difficile infections: Analysis of six-year time-series data in a tertiary-care hospital in Greece. Infection, Disease & Health. 2022.

Papanikolopoulou A, Maltezou HC, Stoupis A, Kalimeri D, Pavli A, Boufidou F, Karalexi M, Pantazis N, Pantos C, Tountas Y, et al. Catheter-Associated Urinary Tract Infections, Bacteremia, and Infection Control Interventions in a Hospital: A Six-Year Time-Series Study. Journal of Clinical Medicine. 2022;11:5418.

Pantazis N, Papastamopoulos V, Antoniadou A, Adamis G, Paparizos V, Metallidis S, Sambatakou H, Psichogiou M, Chini M, Chrysos G, et al. Changes in Body Mass Index after Initiation of Antiretroviral Treatment: Differences by Class of Core Drug. Viruses. 2022;14:1677.

Blenkinsop A, Monod M, van Sighem A, Pantazis N, Bezemer D, de Coul EO, van de Laar T, Fraser C, Prins M, Reiss P, et al. Estimating the potential to prevent locally acquired HIV infections in a UNAIDS Fast-Track City, Amsterdam. eLife. 2022;11:e76487.

Farmakis ETR, Beer F, Tzoutzas I, Kurzmann C, Shokoohi-Tabrizi HA, Pantazis N, Moritz A. Influence of Laser Irradiation Settings, during Diode-Assisted Endodontics, on the Intraradicular Adhesion of Self-Etch and Self-Curing Luting Cement during Restoration—An Ex Vivo Study. Materials. 2022;15:2531.

Papanikolopoulou A, Maltezou HC, Kritikou H, Papadopoulos T, Kandalepas G, Pentzouris A, Kartsonakis I, Chronopoulou G, Gargalianos-Kakolyris P, Pantazis N, et al. Six-Year Time-Series Data on Multidrug-Resistant Bacteremia, Antibiotic Consumption, and Infection Control Interventions in a Hospital. Microbial Drug Resistance. 2022;28:806–818.

Piagkou M, Kostares M, Duparc F, Papanagiotou P, Politis C, Tsakotos G, Pantazis N, Natsis K. The sphenoidal emissary foramina prevalence: a meta-analysis of 6,369 subjects. Surgical and Radiologic Anatomy. 2022:1–11.

Papanikolopoulou A, Maltezou HC, Stoupis A, Pangalis A, Kouroumpetsis C, Chronopoulou G, Kalofissoudis Y, Kostares E, Boufidou F, Karalexi M, et al. Ventilator-Associated Pneumonia, Multidrug-Resistant Bacteremia and Infection Control Interventions in an Intensive Care Unit: Analysis of Six-Year Time-Series Data. Antibiotics. 2022;11:1128.

Group ACTIV-3/TICOS. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Annals of internal medicine. 2022;175:1401–1410.

Papanikolopoulou A, Maltezou HC, Gargalianos-Kakolyris P, Michou I, Kalofissoudis Y, Moussas N, Pantazis N, Kotteas E, Syrigos K, Pantos C, et al. Central line-associated bloodstream infections, multidrug-resistant bacteraemias and infection control interventions: a six-year time-series analysis in a tertiary-care hospital in Greece. Journal of Hospital Infection. 2022.

Group* ACTIV-3/TICOS. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial. Annals of internal medicine. 2022.

Hatzakis A, Karabinis A, Roussos S, Pantazis N, Degiannis D, Chaidaroglou A, Petsios K, Pavlopoulou I, Tsiodras S, Paraskevis D, et al. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination. Vaccines. 2022;10:285.

Thomadakis C, Meligkotsidou L, Pantazis N, Touloumi G. Rejoinder to "Biased Estimation With Shared Parameter Models in the Presence of Competing Dropout Mechanisms". Biometrics. 2021;13437.

Berdouses ED, Michalaki M, Tsinidou K, Vlachou A, Pantazis N, Oulis CJ. Effectiveness of fissure sealants on initial caries lesions (ICDAS 1-3) of permanent molars: A 4-year follow-up. European Journal of Paediatric Dentistry. 2021;22:180–188.

Glaubius R, Kothegal N, Birhanu S, Jonnalagadda S, Mahiane SG, Johnson LF, Brown T, Stover J, Mangal TD, Pantazis N, et al. Disease progression and mortality with untreated HIV infection: evidence synthesis of HIV seroconverter cohorts, antiretroviral treatment clinical cohorts and population-based survey data. Journal of the International AIDS Society. 2021;24:e25784.

Vourli G, Katsarolis I, Pantazis N, Touloumi G. HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. BMC Public Health. 2021;21:1–10.

Pantazis N, Rosinska M, Quinten C, Noori T, Burns F, Kirwan PD, O'Donnell K, Paraskevis D, Sommen C, Zenner D, et al. Discriminating between pre-migration and post-migration HIV acquisition using surveillance data. Journal of Acquired Immune Deficiency Syndromes (1999). 2021.

Thomadakis C, Meligkotsidou L, Pantazis N, Touloumi G. Misspecifying the Covariance Structure in a Linear Mixed Model Under MAR Drop-Out. Statistics in Medicine. 2020:10–1002.

Fragkou PC, Papaevangelou V, Antoniadou A, Kavvatha D, Ploussi A, Pantazis N, Sirmpilantze T, Psarrakis C, Pournaras SA, Tsiodras S, et al. Preliminary Data of a Quantitative Point of Care Test for SARS-CoV-2 Antibodies From Greece. In Vivo. 2020;34:3039–3045.

d'Arminio Monforte A, Bonnet F, Bucher HC, Pourcher V, Pantazis N, Pelchen-Matthews A, Touloumi G, Wolf E. What do the changing patterns of comorbidity burden in people living with HIV mean for long-term management? Perspectives from European HIV cohorts. HIV medicine. 2020;21:3–16.

Papadopoulos A, Ribera A, Mavrogenis AF, Rodriguez-Pardo D, Bonnet E, Salles MJ, del Toro MD, Nguyen S, Blanco-Garcia A, Skaliczki G, et al. Corrigendum to" Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration"[International Journal of Antimicrobial Agents 53 (3)(2019) 294-301]. International journal of antimicrobial agents. 2019;53:538–539.

Skandalakis GP, Koutsarnakis C, Pantazis N, Kalyvas A, Komaitis S, Lani E, Drosos E, Kalamatianos T, Hadjipanayis CG, Natsis K, et al. The carotico-clinoid bar: A systematic review and meta-analysis of its prevalence and potential implications in cerebrovascular and skull base surgery. World neurosurgery. 2019.

van Santen DK, van der Helm JJ, Touloumi G, Pantazis N, Muga R, Gunsenheimer-Bartmeyer B, Gill JM, Sanders E, Kelleher A, Zangerle R, et al. Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids. 2019;33:327–337.

Koumarianou A, Krivan S, Machairas N, Ntavatzikos A, Pantazis N, Schizas D, Martikos G, Kampoli K, Misiakos EP, Patapis P, et al. Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Annals of Gastroenterology. 2019;32:99.

Pantazis N, Papastamopoulos V, Paparizos V, Metallidis S, Adamis G, Antoniadou A, Psychogiou M, Chini M, Sambatakou H, Sipsas NV, et al. Long-term evolution of CD4 cell count in patients under cART. AIDS. 2019.

Paraskevis D, Beloukas A, Stasinos K, Pantazis N, de Mendoza C, Bannert N, Meyer L, Zangerle R, Gill J, Prins M, et al. HIV-1 molecular transmission clusters in nine European countries and Canada: association with demographic and clinical factors. BMC medicine. 2019;17:4.

Pantazis N, Chini M, Antoniadou A, Sambatakou H, Skoutelis A, Gargalianos P, Kourkounti S, Gogos C, Chrysos G, Psichogiou M, et al. The HIV patient profile in 2013 and 2003: Results from the Greek AMACS cohort. PloS one. 2018;13:e0203601.

Tatsis N, Kakavas S, Metaxas E, Balis E, Tatsis G, Pantazis N, Bakakos P, Koulouris N, Hadjistavrou K. Spirometric Values of Greek People and Comparison with ECSC and GLI Values in COPD People. The open respiratory medicine journal. 2018;12:29.

Rosinska M, Pantazis N, Janiec J, Pharris A, Amato-Gauci AJ, Quinten C, Network AIDSS. Potential adjustment methodology for missing data and reporting delay in the HIV Surveillance System, European Union/European Economic Area, 2015. Eurosurveillance. 2018;23.

Soodla P, Simmons R, Huik K, Pauskar M, Jogeda E-L, Rajasaar H, Kallaste E, Maimets M, Avi R, Murphy G, et al. HIV incidence in the Estonian population in 2013 determined using the HIV-1 limiting antigen avidity assay. HIV medicine. 2018;19:33–41.

Thomadakis C, Meligkotsidou L, Pantazis N, Touloumi G. Longitudinal and Time-to-Drop-out Joint Models Can Lead to Seriously Biased Estimates when the Drop-out Mechanism Is at Random. Biometrics. 2018.

Papadopoulos A, Ribera A, Mavrogenis A, Rodriguez-Pardo D, Bonnet E, Salles MJ, del Toro MD, Nguyen S, Garcia AB, Skaliczki G, et al. Multidrug (MDR) and extensively drug resistant (XDR) Gram negative prosthetic joint infections (PJI): Role of surgery and impact of colistin administration. International journal of antimicrobial agents. 2018.

Stirrup OT, Copas AJ, Phillips AN, Gill MJ, Geskus RB, Touloumi G, Young J, Bucher HC, Babiker AG, in EuroCoord CASCADEC, et al. Predictors of CD 4 cell recovery following initiation of antiretroviral therapy among HIV-1 positive patients with well-estimated dates of seroconversion. HIV medicine. 2018;19:184–194.

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical infectious diseases. 2018;66:893–903.

Andritsou F, Benetou V, Michail KA, Pantazis N, Pavlopoulou ID. The increasing consumption of unprescribed antibiotics by Greek preschool children amounts to unacceptable malpractice. Acta Paediatrica. 2017.

Smolen-Dzirba J, Rosinska M, Kruszynski P, Bratosiewicz-Wkasik J, Wojtyczka R, Janiec J, Szetela B, Beniowski M, Bocikaga-Jasik M, Jablonowska E, et al. Prevalence of Transmitted Drug-Resistance Mutations and Polymorphisms in HIV-1 Reverse Transcriptase, Protease, and gp41 Sequences Among Recent Seroconverters in Southern Poland. Medical science monitor: international medical journal of experimental and clinical research. 2017;23:682.

Observational HIV. Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Aids. 2017;31:835–846.

Ghosn J, Bayan T, Meixenberger K, Tran L, Frange P, d’Arminio Monforte A, Zangerle R, de Mendoza C, Krastinova E, Porter K, et al. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. Journal of Antimicrobial Chemotherapy. 2017;72:2862–2868.

Nakagawa F, others. An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. Aids. 2017;31:417–425.

Andritsou F, Benetou V, Michail KA, Pantazis N, Pavlopoulou ID. Out-of-Hospital Administration of Medication without Prescription and Associated Factors among Preschool Children. BioMed research international. 2017;2017.

Smolen-Dzirba J, Rosinska M, Janiec J, Beniowski M, Cycon M, Bratosiewicz-Wkasik J, Wkasik TJ, others. HIV-1 Infection in Persons Homozygous for CCR5-Delta32 Allele: The Next Case and the Review. AIDS reviews. 2017;19:219–230.

Pantazis N, Thomadakis C, Del Amo J, Alvarez-del Arco D, Burns FM, Fakoya I, Touloumi G. Determining the likely place of HIV acquisition for migrants in Europe combining subject-specific information and biomarkers data. Statistical methods in medical research. 2017:0962280217746437.

Lodi S, Costagliola D, Sabin C, Del Amo J, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco J-R, et al. Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;76:311–318.

Fearnhill E, Gourlay A, Malyuta R, Simmons R, Ferns BR, Grant P, Nastouli E, Karnets I, Murphy G, Medoeva A, et al. A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations. Clinical Infectious Diseases. 2017;65:1127–1135.

Bouteloup V, Sabin C, Mocroft A, Gras L, Pantazis N, Le Moing V, d'Arminio Monforte A, Mary-Krause M, Roca B, Miro JM, et al. Reference curves for CD 4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naive patients. HIV medicine. 2017;18:33–44.

Mangal TD. Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. AIDS (London, England). 2017;31:1073.

Grady C, Touloumi G, Walker SA, Smolskis M, Sharma S, Babiker AG, Pantazis N, Tavel J, Florence E, Sanchez A, et al. A randomized trial comparing concise and standard consent forms in the START trial. PloS one. 2017;12:e0172607.

Fidler S, Olson AD, Bucher HC, Fox J, Thornhill J, Morrison C, Muga R, Phillips A, Frater J, Porter K. Virological blips and predictors of post treatment viral control after stopping ART started in primary HIV infection. Journal of acquired immune deficiency syndromes (1999). 2017;74:126.

Alvarez-del Arco D, Fakoya I, Thomadakis C, Pantazis N, Touloumi G, Gennotte A-F, Zuure F, Barros H, Staehelin C, Gopel S, et al. High levels of postmigration HIV acquisition within nine European countries. Aids. 2017;31:1979–1988.

Song R, Hall IH, Green TA, Szwarcwald CL, Pantazis N. Using CD4 data to estimate HIV incidence, prevalence, and percent of undiagnosed infections in the United States. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017;74:3–9.

Karamanolaki H, Spyropoulou AC, Iliadou A, Vousoura E, Vondikaki S, Pantazis N, Vaslamatzis G. Birth order and memories of traumatic and family experiences in Greek patients with borderline personality disorder versus patients with other personality disorders. Bulletin of the Menninger Clinic. 2016;80:234–254.

Judd A, Collins I, Lodi S, Olson A, Pantazis N, Del Amo J, Duff C, Gennotte A-F, Kristensen D, Ledergerber B, et al. Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future. EUROSURVEILLANCE. 2016;21:20–26.

Pantazis N, Touloumi G, Meyer L, Olson A, Costagliola D, Kelleher AD, Lutsar I, Chaix M-L, Fisher M, Moreno S, et al. The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. AIDS (London, England). 2016;30:879.

Simmons R, Malyuta R, Chentsova N, Karnets I, Murphy G, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K, et al. HIV Incidence Estimates Using the Limiting Antigen Avidity EIA Assay at Testing Sites in Kiev City, Ukraine: 2013-2014. PloS one. 2016;11:e0157179.

Olson AD, Walker SA, Suthar AB, Sabin C, Bucher HC, Jarrin I, Moreno S, Perez-Hoyos S, Porter K, Ford D. Limiting cumulative HIV viremia copy-years by early treatment reduces risk of AIDS and death. Journal of acquired immune deficiency syndromes (1999). 2016;73:100.

Nakagawa F, van Sighem A, Thiebaut R, Smith C, Ratmann O, Cambiano V, Albert J, Amato-Gauci A, Bezemer D, Campbell C, et al. A method to estimate the size and characteristics of HIV-positive populations using an individual-based stochastic simulation model. Epidemiology (Cambridge, Mass.). 2016;27:247.

Farmakis E-TR, Palamidakis FD, Skondra FG, Nikoloudaki G, Pantazis N. Emergency care provided in a Greek dental school and analysis of the patients’ demographic characteristics: a prospective study. International dental journal. 2016;66:280–286.

Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, Willberg CB, Robinson N, Brown H, Fisher M, et al. Exhaustion of activated CD8 T cells predicts disease progression in primary HIV-1 infection. PLoS pathogens. 2016;12:e1005661.

Pantazis N, Psichogiou M, Paparizos V, Gargalianos P, Chini M, Protopapas K, Sipsas NV, Panos G, Chrysos G, Sambatakou H, et al. Treatment Modifications and Treatment-Limiting Toxicities or Side Effects: Risk Factors and Temporal Trends. AIDS research and human retroviruses. 2015;31:707–717.

Boosted lopinavir–versus boosted atazanavir–containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clinical Infectious Diseases. 2015;60:1262–1268.

Simmons R, Malyuta R, Chentsova N, Medoeva A, Kruglov Y, Yurchenko A, Copas A, Porter K, in EuroCoord CASCADEC, others. HIV testing and diagnosis rates in Kiev, Ukraine: April 2013-March 2014. PloS one. 2015;10:e0137062.

Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, et al. Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?. AIDS (London, England). 2015;29:2323.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miro JM, Ferrer E, et al. Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. The lancet HIV. 2015;2:e335–e343.

Simmons R, Semenenko I, Tolpina M, Tereschenko R, Kotlik L, Zasyptka L, Murphy G, McKinney E, Copas A, Malyuta R, et al. High percentage of recent HIV infection leading to onward transmission in Odessa, Ukraine associated with young adults. AIDS and Behavior. 2014;18:411–418.

Olson AD, Guiguet M, Zangerle R, Gill J, Perez-Hoyos S, Lodi S, Ghosn J, Dorrucci M, Johnson A, Sannes M, et al. Evaluation of rapid progressors in HIV infection as an extreme phenotype. Journal of acquired immune deficiency syndromes (1999). 2014;67:15.

Nakagawa F, Grp NHPW, Ep COHIV, others. Factors associated with short-term changes in HIV viral load and CD4 R cell count in antiretroviral-naive individuals. Aids. 2014;28:1351–1356.

Pantazis N, Porter K, Costagliola D, de Luca A, Ghosn J, Guiguet M, Johnson AM, Kelleher AD, Morrison C, Thiebaut R, et al. Temporal trends in prognostic markers of HIV-1 virulence and transmissibility: an observational cohort study. The Lancet HIV. 2014;1:e119–e126.

Asayama K, Thijs L, Brguljan-Hitij J, Niiranen TJ, Hozawa A, Boggia J, Aparicio LS, Hara A, Johansson JK, Ohkubo T, et al. Risk stratification by self-measured home blood pressure across categories of conventional blood pressure: a participant-level meta-analysis. PLoS medicine. 2014;11:e1001591.

Olson AD, Meyer L, Prins M, Thiebaut R, Gurdasani D, Guiguet M, Chaix M-L, Amornkul P, Babiker A, Sandhu MS, et al. An evaluation of HIV elite controller definitions within a large seroconverter cohort collaboration. PloS one. 2014;9:e86719.

Pantazis N, Kenward MG, Touloumi G. Performance of parametric survival models under non-random interval censoring: A simulation study. Computational statistics & data analysis. 2013;63:16–30.

Paraskevis D, Touloumi G, Bakoyannis G, Paparizos V, Lazanas M, Gargalianos P, Chryssos G, Antoniadou A, Psichogiou M, Panos G, et al. Effect of HIV type 1 subtype on virological and immunological response to combination antiretroviral therapy: evidence for a more rapid viral suppression for subtype A than subtype B-infected Greek individuals. AIDS research and human retroviruses. 2013;29:461–469.

Lodi S, Fisher M, Phillips A, de Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, et al. Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PloS one. 2013;8:e78642.

Touloumi G, Pantazis N, Chaix M-L, Bucher HC, Zangerle R, Kran A-MB, Thiebaut R, Masquelier B, Kucherer C, d'Arminio Monforte A, et al. Virologic and immunologic response to cART by HIV-1 subtype in the CASCADE collaboration. PloS one. 2013;8:e71174.

Rosinska M, Marzec-Bogustawska A, Janiec J, Smolen-Dzirba J, Wkasik T, Gniewosz J, Zalewska M, Murphy G, McKinney E, Porter K. High percentage of recent HIV infection among HIV-positive individuals newly diagnosed at voluntary counseling and testing sites in Poland. AIDS research and human retroviruses. 2013;29:805–813.

Lodi S, Del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E, et al. Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax. 2013;68:207–213.

Farmakis E-TR, Beer F, Kozyrakis K, Pantazis N, Moritz A. The influence of different power settings of Nd: YAG laser irradiation, bioglass and combination to the occlusion of dentinal tubules. Photomedicine and laser surgery. 2013;31:54–58.

Farmakis ETR, Sotiropoulos GG, Pantazis N, Kozyrakis K. The permanent deformation of the self-adjusting files when used in canals of extracted teeth. International endodontic journal. 2013;46:863–869.

Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d’Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, et al. Natural history of HIV-control since seroconversion. Aids. 2013;27:2451–2460.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, et al. Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2013;62:441–446.

van der Helm J, Geskus R, Sabin C, Meyer L, Del Amo J, Chene G, Dorrucci M, Muga R, Porter K, Prins M, et al. Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997. Gastroenterology. 2013;144:751–760.

Papadopoulos A, Pantazis N, Panagopoulos P, Kourkounti S, Xylomenos G, Chini M, Petrikkos G, Sambatakou H, Ioannidou P, Kordosis T, et al. Effects of first antiretroviral regimen on lipid levels in HIV (+) individuals. Journal of Chemotherapy. 2012;24:38–47.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix M-L, Babiker A, Porter K, others. Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection. Antiviral therapy. 2012;17:1039.

, others. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS (London, England). 2012;26:1691.

Collaborationa HIV-CAUSAL. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clinical infectious diseases. 2012;54:1364–1372.

Pantazis N, Morrison C, Amornkul PN, Lewden C, Salata RA, Minga A, Chipato T, Jaffe H, Lakhi S, Karita E, et al. Differences in HIV natural history among African and non-African seroconverters in Europe and seroconverters in sub-Saharan Africa. PloS one. 2012;7:e32369.

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Archives of internal medicine. 2012;172:1252–1255.

Touloumi G, Pantazis N, Pillay D, Paraskevis D, Chaix M-L, Bucher HC, Kucherer C, Zangerle R, Kran A-MB, Porter K, et al. Impact of HIV-1 subtype on CD4 count at HIV seroconversion, rate of decline, and viral load set point in European seroconverter cohorts. Clinical infectious diseases. 2012;56:888–897.

Mussini C, Cossarizza A, Sabin C, Babiker A, de Luca A, Bucher HC, Fisher M, Rezza G, Porter K, Dorrucci M, et al. Decline of CD4+ T-cell count before start of therapy and immunological response to treatment in antiretroviral-naive individuals. Aids. 2011;25:1041–1049.

Jarrin I, Pantazis N, Gill JM, Geskus R, Perez-Hoyos S, Meyer L, Prins M, Touloumi G, Johnson A, Hamouda O, et al. Uptake of combination antiretroviral therapy and HIV disease progression according to geographical origin in seroconverters in Europe, Canada, and Australia. Clinical infectious diseases. 2011;54:111–118.

Jaffe HW, De Stavola BL, Carpenter LM, Porter K, Cox DR, Collaboration C, others. Immune reconstitution and risk of Kaposi sarcoma and non-Hodgkin lymphoma in HIV-infected adults. Aids. 2011;25:1395–1403.

van der Helm JJ, Prins M, Del Amo J, Bucher HC, Chene G, Dorrucci M, Gill J, Hamouda O, Sannes M, Porter K, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. Aids. 2011;25:1083–1091.

Funk MJ, Fusco JS, Cole SR, Thomas JC, Porter K, Kaufman JS, Davidian M, White AD, Hartmann KE, Eron Jr JJ, et al. Timing of HAART initiation and clinical outcomes among HIV-1 seroconverters. Archives of internal medicine. 2011;171:1560.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiebaut R, Pantazis N, Del Amo J, Johnson AM, Babiker A, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds< 200,< 350, and< 500 cells/mm3: assessment of need following changes in treatment guidelines. Clinical infectious diseases. 2011;53:817–825.

Pantazis N, Touloumi G. Analyzing longitudinal data in the presence of informative drop-out: The jmre1 command. Stata Journal. 2010;10:226–251.

Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chene G, Vanhems P, Porter K, Collaboration C, et al. CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era. AIDS. 2010;24:2697–2704.

Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet (London, England). 2010;376:340–345.

Wolbers M, Babiker A, Sabin C, Young J, Dorrucci M, Chene G, Mussini C, Porter K, Bucher HC, Collaboration C, et al. Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy—the CASCADE collaboration: a collaboration of 23 cohort studies. PLoS medicine. 2010;7:e1000239.

Stergiou GS, Nasothimiou EG, Kalogeropoulos PG, Pantazis N, Baibas NM. The optimal home blood pressure monitoring schedule based on the Didima outcome study. Journal of human hypertension. 2010;24:158.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K, Collaboration C. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Journal of the National Cancer Institute. 2010;102:784–792.

Brown AE, Gifford RJ, Clewley JP, Kucherer C, Masquelier B, Porter K, Ballota C, Back NKT, Jorgensen LB, de Mendoza C, et al. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. The Journal of infectious diseases. 2009;199:427–431.

Bohlius J, Schmidlin K, Costagliola D, Fatkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antiviral therapy. 2009;14:1065.

Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, Hamouda O, Prins M, Walker SA, Porter K, et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (London, England). 2009;23:1743.

Guiguet M, Porter K, Phillips A, Costagliola D, Babiker A. Clinical progression rates by CD4 cell category before and after the initiation of combination antiretroviral therapy (cART). The open AIDS journal. 2008;2:3.

Touloumi G, Pantazis N, Stirnadel HA, Walker SA, Boufassa F, Vanhems P, Porter K, Collaboration C, others. Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2008;49:492–498.

Pantazis N, Touloumi G, Vanhems P, Gill J, Bucher HC, Porter K, Collaboration C, others. The effect of antiretroviral treatment of different durations in primary HIV infection. Aids. 2008;22:2441–2450.

Georgopoulou MK, Spanaki-Voreadi AP, Pantazis N, Kontakiotis EG, Morfis AS. Periapical status and quality of root canal fillings and coronal restorations in a Greek population. Quintessence international. 2008;39.

Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, Porter K, Collaboration C, others. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. Jama. 2008;300:51–59.

Dunn D, Woodburn P, Duong T, Peto J, Phillips A, Gibb D, Porter K, (HPPMCS) HIVPPMCS, on to AIDS CAS-C, in Collaboration DE (CASCADE). Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults. The Journal of infectious diseases. 2008;197:398–404.

Jarrin I, Geskus R, Bhaskaran K, Prins M, Perez-Hoyos S, Muga R, Hernandez-Aguado I, Meyer L, Porter K, Del Amo J. Gender differences in HIV progression to AIDS and death in industrialized countries: slower disease progression following HIV seroconversion in women. American journal of epidemiology. 2008;168:532–540.

of Group COHIVERE (COHERE) S, others. Response to combination antiretroviral therapy: variation by age. Aids. 2008;22:1463–1473.

Pantazis N, Touloumi G. Robustness of a parametric model for informatively censored bivariate longitudinal data under misspecification of its distributional assumptions: A simulation study. Statistics in medicine. 2007;26:5473–5485.

Fidler S, Fox J, Touloumi G, Pantazis N, Porter K, Babiker A, Weber J, Collaboration C, others. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIdS. 2007;21:1283–1291.

Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K, Collaboration C, others. Highly active antiretroviral therapy interruption: predictors and virological and immunologic consequences. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006;42:554–561.

Pantazis N, Touloumi G, Walker AS, Babiker AG. Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop-outs. Journal of the Royal Statistical Society: Series C (Applied Statistics). 2005;54:405–423.

Georgopoulou MK, Spanaki-Voreadi AP, Pantazis N, Kontakiotis EG. Frequency and distribution of root filled teeth and apical periodontitis in a Greek population. International endodontic journal. 2005;38:105–111.

Touloumi G, Pantazis N, Karafoulidou A, Mandalaki T, Goedert JJ, Kostrikis LG, Hatzakis A. Changes in T cell receptor excision DNA circle (TREC) levels in HIV type 1-infected subjects pre-and post-highly active antiretroviral therapy. AIDS research and human retroviruses. 2004;20:47–54.

Hatzakis AE, Touloumi G, Pantazis N, Anastassopoulou CG, Katsarou O, Karafoulidou A, Goedert JJ, Kostrikis LG. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. Aids. 2004;18:2261–2267.

Touloumi G, Pantazis N, Babiker AG, Walker SA, Katsarou O, Karafoulidou A, Hatzakis A, Porter K, Collaboration C, others. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. Aids. 2004;18:1697–1705.

Sipsas NV, Sfikakis PP, Touloumi G, Pantazis N, Choremi H, Kordossis T. Elevated serum levels of soluble immune activation markers are associated with increased risk for death in HAART-naive HIV-1–infected patients. AIDS patient care and STDs. 2003;17:147–153.

Giota Touloumi, Nikos Pantazis ABSWOKAHAKKPA, Janet Darbyshire CASCADEC. Differences in CD4 Cell Counts at Seroconversion and Decline Among 5739 HIV-1–Infected Individuals with Well-Estimated Dates of Seroconversion. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2003;34:76–83.

Kostrikis LG, Touloumi G, Karanicolas R, Pantazis N, Anastassopoulou C, Karafoulidou A, Goedert JJ, Hatzakis A, Group MHCS, others. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. Journal of virology. 2002;76:10099–10108.

Ioannidis JPA, Haidich A-B, Pappa M, Pantazis N, Kokori SI, Tektonidou MG, Contopoulos-Ioannidis DG, Lau J. Comparison of evidence of treatment effects in randomized and nonrandomized studies. Jama. 2001;286:821–830.